MYCN and neuroblastoma: Although patients with low risk respond well to treatment, majority of the NB patients are detected with malignant metastatic spread and 40–50% of these high-risk patients have N-myc oncogene amplification, which is one of the key prognostic factor of poor outcome in advanced stage NB.